脉管复康片联合西洛他唑治疗下肢动脉硬化闭塞症的临床研究  

Clinical study on Maiguan Fukang Tablets combined with cilostazol in treatment of lower extremity arteriosclerosis obliterans

作　　者：朱盛兴 张雷 焦小平 牛哲 刘秀梅 ZHU Sheng-xing;ZHANG Lei;JIAO Xiao-ping;NIU Zhe;LIU Xiu-mei(Department of Vascular Surgery,People’s Hospital of Henan University of Chinese Medicine(People’s Hospital of Zhengzhou),Zhengzhou 450003,China;Department of Clinical Pharmacy,People's Hospital of Henan University of Chinese Medicine(People's Hospital of Zhengzhou),Zhengzhou 450003,China)

机构地区：[1]河南中医药大学人民医院郑州人民医院血管外科,河南郑州450003 [2]河南中医药大学人民医院郑州人民医院临床药学科,河南郑州450003

出　　处：《现代药物与临床》2021年第12期2569-2573,共5页Drugs & Clinic

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20191071)。

摘　　要：目的观察脉管复康片联合西洛他唑片治疗下肢动脉硬化闭塞症的临床疗效。方法选取2019年4月—2020年12月河南中医药大学人民医院(郑州人民医院)收治68例下肢动脉硬化闭塞症患者,根据随机数字表法分为对照组和治疗组,每组各34例。对照组口服西洛他唑片,1片/次,2次/d。治疗组在对照组治疗的基础上口服脉管复康片,4片/次,3次/d。两组患者治疗8周。观察两组的临床疗效,比较两组的动脉硬化指标、血流动力学指标、血管内皮功能指标。结果治疗后,治疗组的总有效率为88.24%,高于对照组的67.65%(P<0.05)。治疗后,两组踝肱指数(ABI)升高,血管内径扩大,峰值流速降低,血流量增加(P<0.05),且治疗后,治疗组峰值流速低于对照组,ABI、血流量、血管内径高于对照组(P<0.05)。治疗后,两组全血低切黏度、全血高切黏度、血浆黏度、细胞沉降率降低(P<0.05),且治疗后,治疗组全血低切黏度、全血高切黏度、血浆黏度、细胞沉降率低于对照组(P<0.05)。治疗后,两组内皮素-1(ET-1)、血栓素B2降低,6-酮-前列腺素F1α(6-keto-PGF1α)、一氧化氮(NO)升高(P<0.05),且治疗后,治疗组ET-1、血栓素B2低于对照组,6-ketoPGF1α、NO高于对照组(P<0.05)。结论脉管复康片联合西洛他唑片治疗下肢动脉硬化闭塞症具有较好疗效,可提高ABI,减轻下肢缺血症状,促进局部血液循环,改善血管内皮功能,有一定的应用价值。Objective To observe the clinical efficacy of Maiguan Fukang Tablets combined with Cilostazol Tablets in treatment of lower extremity arteriosclerosis obliterans. Methods Patients(68 cases) with lower extremity arteriosclerosis obliterans in People’s Hospital of Henan University of Chinese Medicine(People’s Hospital of Zhengzhou) from April 2019 to December 2020 were randomly divided into control and treatment groups, and each group had 34 cases. Patients in the control group were po administered with Cilostazol Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Maiguan Fukang Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and arteriosclerosis index, hemodynamic index, and vascular endothelial function index in two groups were compared. Results After treatment, the total effective rate in the treatment group was 88.24%, which was higher than 67.65% in the control group(P < 0.05). After treatment, the ABI in two groups were increased, but the vessel diameter expanded, peak flow rate in two groups were decreased, and the blood flow in two groups were increased(P < 0.05). After treatment, the peak flow rate in the treatment group was lower than that in the control group, and the ABI, blood flow, and vessel diameter in the treatment group were higher than those in the control group(P < 0.05). After treatment, the whole blood low shear viscosity, whole blood high shear viscosity, plasma viscosity, and cell sedimentation rate in two groups were decreased(P < 0.05), and the whole blood low shear viscosity, whole blood high shear viscosity, plasma viscosity, and cell sedimentation rate in the treatment group were lower than those in the control group(P < 0.05). After treatment, the ET-1 and thromboplug B2 in two groups were decreased, but the 6-keto-PGF1α and NO in two groups were increased(P < 0.05). After treatment, the ET-1 and thrombo

关 键 词：脉管复康片 西洛他唑片 下肢动脉硬化闭塞症 动脉硬化指标 血流动力学指标 血管内皮功能指标 

分 类 号：R973[医药卫生—药品]